European Rare Diseases Research Alliance: planned call and webinar (17/12/2024)

The initiative European Rare Diseases Research Alliance (ERDERA) has announced preliminary information about its planned call for international projects “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”. The call is planned to open on 10. 12. 2024, planned deadline for pre-proposals is 13. 2. 2025.

Participation of Czech entities will be funded via the Czech Health Research Council (AZV).

On 17. 12. 2024, ERDERA organise a webinar for applicants. Information about the event will hopefully be published on ERDERA website.

If you plan to participate in a proposal, please, contact well in advance, 1 month before the deadline at the latest, the Project Management Department (Martina Holíková, martina.holikova@natur.cuni.cz), so that all the formal requirements of the application can be prepared in time.

If you consider coordinating a project, please contact us as soon as possible, ca. 2 months before the deadline at the very latest.

• About the call on ERDERA website – basic information, call timeline etc.
• Call for Proposals 2025 pre-announcement – participating countries, supported topics, rules of participation etc.
• About the call on AZV website – basic information for Czech applicants.

The call will to support interdisciplinary, transnational collaborations that should develop new therapies for rare diseases. Projects should focus on pre-clinical studies involving small molecules or biologicals. This could include the development of novel therapies, biomarkers for therapy efficiency, or replication of pre-clinical studies to validate findings.

Project duration is up to 3 years. Project consortium must consist of 4–6 partners (principal investigators) from at least 4 countries participating in the call. At least one partner must be an “Early Career Researcher” (a researcher who has received their PhD, or a medical doctor who has completed their specialist medical training, no more than 7 years before the application deadline). Maximal number of partners is increased to 8, if the 1–2 “additional” partners are additional “Early Career Researcher” or are from one of the “underrepresented countries” (e.g., Czechia). No more than 2 partners from 1 country can participate in one proposal.
Each partner must fulfil the eligibility criteria of their national funding body.

Countries preliminarily planning to participate in the call: Austria, Belgium, Bulgaria, Canada, Cyprus, Czechia, Denmark, Estonia, France, Germany, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Netherlands, Türkiye.

Funding of participation of Czech entities will be linked to the Applied Health Research Support Program for 2024 – 2030, Sub-programme 3: European Partnerships in Health. Total AZV financial allocation for this call is EUR 500 000.

News published by Ludmila Součková on 18. 10. 2024.

Not the information you sought? Found a mistake? Please, let us know.